Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
AUTOR(ES)
Sabatino, Marianna
FONTE
American Society of Clinical Oncology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2689845Documentos Relacionados
- Cardiomyopathy associated with high-dose interleukin-2 therapy.
- Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.
- High-dose narrative
- Peripheral neuropathy during longterm high-dose amiodarone therapy.
- Effect of saturable clearance during high-dose mezlocillin therapy.